Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution
- 1 August 2011
- journal article
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 213 (2) , 306-316
Abstract
Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) are used to manage advanced extremity melanoma, but no consensus exists as to which treatment is preferable and how to monitor patients post-treatment. Using a prospectively maintained database, we reviewed our experience with melphalan-based HILP (which included 62 first-time and 10 second-time) and ILI (which included 126 first-time and 18 second-time) procedures performed in 188 patients. PET/CT was obtained 3 months postregional treatment for 1 year and then every 6 months thereafter. Overall response rate (complete response [CR] + partial response) of HILP was 81% (80% CI, 73-87%), and overall response rate from ILI was 43% (80% CI, 37-49%) for first-time procedures only. HILP had a CR rate of 55% with a median duration of 32 months, and ILI had a CR rate of 30% with median duration of 24 months. Patients who experienced a regional recurrence after initial regional treatment were more likely to achieve a CR after repeat HILP (50%, n = 10) compared with repeat ILI (28%, n = 18). Although the spectrum of toxicity was similar for ILI and HILP, the likelihood of rare catastrophic complication of limb loss was greater with HILP (2 of 62) than ILI (0 of 122). PET/CT was effective for surveillance after regional therapy to identify regional nodal and pulmonary disease that was not clinically evident, but often amenable to surgical resection (25 of 49; 51% of cases). In contrast, PET/CT was not effective at predicting complete response to treatment with an accuracy of only 50%. In the largest single-institution regional therapy series reported to date, we found that although ILI is effective and well-tolerated, HILP is a more definitive way to control advanced disease.Keywords
This publication has 37 references indexed in Scilit:
- Utility of Preoperative 18F-FDG PET/CT and Brain MRI in Melanoma Patients with Palpable Lymph Node MetastasesAnnals of Surgical Oncology, 2010
- Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb InfusionCancers, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the USJournal of the American College of Surgeons, 2009
- The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma modelBiochemical and Biophysical Research Communications, 2008
- Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb PerfusionAnnals of Surgical Oncology, 2008
- Long-term Results of Hyperthermic, Isolated Limb Perfusion for MelanomaAnnals of Surgery, 2007
- Repeat isolated limb perfusion with TNFα and melphalan for recurrent limb melanoma after failure of previous perfusionEuropean Journal of Surgical Oncology, 2006
- Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limbBritish Journal of Surgery, 1990
- Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEuropean Journal of Cancer and Clinical Oncology, 1982